Five generic drugs identified as preventative treatments for COVID-19

In collaboration with the University of Vienna, Austrian biotech company, CEBINA, has identified five generic drugs as potential preventative treatments for COVID-19.

CEBINA, an Austrian biotech company, has announced positive results of its new COVID-19 drug repurposing project. The company has identified previously approved drugs as possible preventative treatments for COVID-19. One of these drugs, Azelastine an antihistamine currently available as a nasal spray, has been identified as a potential topical preventive or post-exposure anti-COVID-19 approach.

In collaboration with Professor Robert Konrat, a renowned structural biologist at University of Vienna, CEBINA has applied a computational approach, integrating several software tools and novel biological pathway analysis, to identify potential preventative treatments for COVID-19.

“We are thrilled to see that our in-silico approach has led to the identification of existing and readily available drugs that have proven anti-SARS-CoV-2 activity, as these findings can have an immediate beneficial effect in the fight against COVID-19,” commented Professor Robert Konrat.

Which drugs can prevent COVID-19 infection?

The results of this study show that five generic drugs demonstrated the ability to function as preventative treatments for COVID-19. The most potent among the identified drugs, Azelastine, is available as a topically applied product and has only modest side-effects. The other identified drugs are commonly used in anti-hypertensive therapy: Telmisartan, Metoprolol, Losartan and Amiloride.

“As the number of COVID-19 cases continues to surge, the identification of Azelastine presents a highly promising preventive and/or post-exposure anti-COVID-19 solution, particularly considering that this drug is widely available as nasal spray and can act directly at the initial site of viral infection.

“We are working towards confirming our findings in a clinical study, especially the observation that a significantly lower dose might be effective. A lower dosage would be expected to reduce the known side effects, which are not significant though potentially unpleasant and could differentiate between the COVID-19 and the anti-allergic indications,” said Eszter Nagy, MD PhD, CEO and founder of CEBINA.

Subscribe to our newsletter


Please enter your comment!
Please enter your name here

Featured Topics

Partner News

Latest eBooks

Latest Partners

Similar Articles

More from Innovation News Network